Full Name
Wee Joo Chng
Variants
Chng W.J
Chng, W.J.
Chng W.-J.
Wee Joo Chng
Chng, W.-J.
 
 
 
Email
mdccwj@nus.edu.sg
 
 

Publications

Refined By:
Date Issued:  [2000 TO 2021]
Type:  Review

Results 1-20 of 35 (Search time: 0.011 seconds).

Issue DateTitleAuthor(s)
123-Feb-2021Application of Advanced Mass Spectrometry-Based Proteomics to Study Hypoxia Driven Cancer ProgressionVinaiphat, Arada; Low, Jee Keem; Yeoh, Kheng Wei ; Chng, Wee Joo ; Sze, Siu Kwan
229-Apr-2021CAR T-cell therapy in multiple myeloma: more room for improvementTeoh, Phaik Ju ; Chng, Wee Joo 
3Oct-2009Centrosomes and myeloma; aneuploidy and proliferationChng, W.J. ; Fonseca, R.
41-Nov-2019Comprehensive Analysis of ERK1/2 Substrates for Potential Combination ImmunotherapiesYang, Lei ; Zheng, Liangzhen; Chng, Wee Joo ; Ding, Jeak Ling 
518-Feb-2021Crosstalk between endoplasmic reticulum stress and oxidative stress: a dynamic duo in multiple myelomaXiong, Sinan; Chng, Wee-Joo ; Zhou, Jianbiao 
61-Mar-2021Daratumumab-based induction therapy for multiple myeloma: A systematic review and meta-analysisChong, Lip Leong; Soon, Yu Yang ; Soekojo, Cinnie Yentia; Ooi, Melissa ; Chng, Wee Joo ; de Mel, Sanjay
72020Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myelomaDimopoulos, M.A.; Jakubowiak, A.J.; McCarthy, P.L.; Orlowski, R.Z.; Attal, M.; Bladé, J.; Goldschmidt, H.; Weisel, K.C.; Ramasamy, K.; Zweegman, S.; Spencer, A.; Huang, J.S.Y.; Lu, J.; Sunami, K.; Iida, S.; Chng, W.-J. ; Holstein, S.A.; Rocci, A.; Skacel, T.; Labotka, R.; Palumbo, A.; Anderson, K.C.
82019EZH2 abnormalities in lymphoid malignancies: Underlying mechanisms and therapeutic implicationsLi, B. ; Chng, W.-J. 
92020Immunoglobulin m paraproteinaemiasGirard, L.-P.; Soekojo, C.Y.; Ooi, M.; Poon, L.M.; Chng, W.-J. ; de Mel, S.
101-Mar-2020Immunotherapy in Multiple MyelomaSoekojo, Cinnie Yentia; Ooi, Melissa ; de Mel, Sanjay; Chng, Wee Joo 
112014Implications of heterogeneity in multiple myelomaDe Mel S.; Lim S.H.; Tung M.L.; Chng W.-J. 
12Feb-2014IMWG consensus on risk stratification in multiple myelomaChng, W.J. ; Dispenzieri, A.; Chim, C.-S.; Fonseca, R.; Goldschmidt, H.; Lentzsch, S.; Munshi, N.; Palumbo, A.; Miguel, J.S.; Sonneveld, P.; Cavo, M.; Usmani, S.; Durie, B.G.; Avet-Loiseau, H.
131-Oct-2021Janus Kinase Signaling: Oncogenic Criminal of Lymphoid CancersLi, Boheng; Wan, Qin; Li, Zhubo; Chng, Wee-Joo 
14Nov-2013Management of multiple myeloma in asia: Resource-stratified guidelinesTan, D.; Chng, W.J. ; Chou, T.; Nawarawong, W.; Hwang, S.-Y.; Chim, C.S.; Chen, W.; Durie, B.G.M.; Lee, J.H.
15Apr-2012Management of treatment-emergent peripheral neuropathy in multiple myelomaRichardson, P.G.; Delforge, M.; Beksac, M.; Wen, P.; Jongen, J.L.; Sezer, O.; Terpos, E.; Munshi, N.; Palumbo, A.; Rajkumar, S.V.; Harousseau, J.L.; Moreau, P.; Avet-Loiseau, H.; Lee, J.H.; Cavo, M.; Merlini, G.; Voorhees, P.; Chng, W.J. ; Mazumder, A.; Usmani, S.; Einsele, H.; Comenzo, R.; Orlowski, R.; Vesole, D.; Lahuerta, J.J.; Niesvizky, R.; Siegel, D.; Mateos, M.-V.; Dimopoulos, M.; Lonial, S.; Jagannath, S.; Bladé, J.; Miguel, J.S.; Morgan, G.; Anderson, K.C.; Durie, B.G.M.; Sonneveld, P.
162014MicroRNA: Important player in the pathobiology of multiple myelomaBi C.; Chng W.J. 
172011miRNA deregulation in multiple myelomaBi C.L.; Chng W.J. 
182014MMSET: Role and therapeutic opportunities in multiple myelomaXie Z.; Chng W.J. 
192-Apr-2019Molecular pathogenic pathways in extranodal NK/T cell lymphomade Mel, Sanjay; Hue, Susan Swee-Shan; Jeyasekharan, Anand D ; Chng, Wee-Joo ; Ng, Siok-Bian 
202014P53 abnormalities and potential therapeutic targeting in multiple myelomaTeoh P.J.; Chng W.J.